A new study compares the regenerative potential of blood/bone marrow aspirate concentrates obtained from arterial blood, venous blood, and bone marrow aspirate. The study, conducted in rabbits, is reported in the peer-reviewed journal Tissue Engineering Part A. Blood concentrate material such as platelet-rick fibrin (PRF) is used in clinical practice to promote tissue regeneration in the
Cedars-Sinai Investigators Found It Also Reduced Scarred Heart Tissue in Animals Vesicles secreted from human heart cells may repair damaged tissue and prevent lethal heart rhythm disorders, according to a new study from investigators in the Smidt Heart Institute at Cedars-Sinai. The research, published in the European Heart Journal, could lead to a new way to
Cell Therapy Developed by Smidt Heart Institute Leader Delays Disease Progression in Patients Who Have Few Treatment Options A cell therapy developed by the executive director of the Smidt Heart Institute stabilizes weakened muscles–including the heart muscle–in Duchenne muscular dystrophy patients, a new study published in the international peer-reviewed journal The Lancet shows. If the HOPE-2 study’s
A new study by University of Manitoba researchers has developed a stem cell-based therapy that may eventually lead to new regenerative treatments for people with spinal cord injuries. Dr. Soheila Karimi, professor of physiology and pathophysiology at the Max Rady College of Medicine, Rady Faculty of Health Sciences, and her colleagues have developed a treatment strategy that
On April 1, 2022, the Food and Drug Administration approved axicabtagene ciloleucel (Yescarta, Kite Pharma, Inc.) for adult patients with large B-cell lymphoma (LBCL) that is refractory to first-line chemoimmunotherapy or relapses within 12 months of first-line chemoimmunotherapy. It is not indicated for the treatment of patients with primary central nervous system lymphoma. Approval was
Natural killer (NK) cells derived from cord blood that were activated and complexed with a CD30/CD16A bispecific antibody elicited an 89 percent overall response rate in patients with relapsed or refractory CD30+ lymphoma, according to results from a phase I/II clinical trial presented at the AACR Annual Meeting 2022, held April 8-13. “We were favorably surprised by the
A MRNA VACCINE WAS COMBINED WITH CAR T CELLS THAT TARGET TUMOR CELLS EXPRESSING THE CLDN6 ANTIGEN A new chimeric antigen receptor (CAR) T-cell product had an acceptable safety profile and showed early signs of efficacy as a monotherapy and in combination with an mRNA vaccine in patients with solid tumors, according to preliminary data
CD19 CAR T-cell therapy is effective at achieving durable remission for relapsed/refractory ALL across cytogenetic risk groups. CD19 CAR T-cell treatment results for patients with high-risk cytogenetics including Ph+, Ph-like, and KMT2A-rearranged ALL are encouraging. Chimeric antigen receptor (CAR) T-cell therapy can induce durable remissions of relapsed/refractory B-acute lymphoblastic leukemia (ALL). However, case reports suggested differential
Stanford researchers have been working on gene therapies for epidermolysis bullosa, or “butterfly disease,” for over a decade. A new gel helped wounds heal and stay healed in a clinical trial. A gene therapy gel applied to the wounds of nine people — three of whom were children — with the blistering skin disease epidermolysis
A study reporting this new protocol was published in the April 7 print edition of the journal Cell Stem Cell. A Mount Sinai-led team has developed a reproducible and scalable method to advance maturation of human pluripotent stem cell-derived cardiomyocytes (hPSC-CMs)—cells that support heart muscle contraction, generated in the lab from human stem cell lines—which researchers
